Homeobox-A13 Acts As a Functional Prognostic and Diagnostic Biomarker Via Regulating P53 and Wnt Signaling Pathways in Lung Cancer.

Yang Wang,Bo He,Yan Dong,Gong-Jing He,Xiao-Wei Qi,Yan Li,Yi-Fei Yang,Yu Rao,Zhong-Shun Cen,Fei Han,Jun Ding,Jian-Jun Li
DOI: https://doi.org/10.3233/cbm-200540
2021-01-01
Abstract:BACKGROUNDThe prognosis of lung cancer patients is poor without useful prognostic and diagnostic biomarker. To search for novel prognostic and diagnostic markers, we previously found homeobox-A13 (HOXA13) as a promising candidate in lung cancer.OBJECTIVETo determine the precisely clinical feature, prognostic and diagnostic value, possible role and mechanism of HOXA13.METHODSGene-expression was explored by real-time quantitative-PCR, western-blot and tissue-microarray. The associations were analyzed by Chi-square test, Kaplan-Meier and Cox-regression. The roles and mechanisms were evaluated by MTS, EdU, transwell, xenograft tumor and luciferase-reporter assays.RESULTSHOXA13 expression is increased in tumors, and correlated with age of patients. HOXA13 expression is associated with unfavorable overall survival and relapse-free survival of patients in four cohorts. Interestingly, HOXA13 has different prognostic significance in adenocarcinoma (ADC) and squamous-cell carcinoma (SCC), and is a sex- and smoke-related prognostic factor only in ADC. Importantly, HOXA13 can serve as a diagnostic biomarker for lung cancer, especially for SCC. HOXA13 can promote cancer-cell proliferation, migration and invasion in vitro, and facilitate tumorigenicity and tumor metastasis in vivo. HOXA13 acts the oncogenic roles on tumor growth and metastasis by regulating P53 and Wnt/β-catenin signaling activities in lung cancer.CONCLUSIONSHOXA13 is a new prognostic and diagnostic biomarker associated with P53 and Wnt/β-catenin signaling pathways.
What problem does this paper attempt to address?